MedPath

Procalcitonin Use in Pneumonia Patients in the Critical Care Setting

Not Applicable
Completed
Conditions
Pneumonia
Interventions
Other: Use of procalcitonin as biomarker to guide therapy
Registration Number
NCT01788488
Lead Sponsor
Mayo Clinic
Brief Summary

The goal of the study is to determine the impact of procalcitonin (PCT)-guided therapy on duration of antibiotic therapy in critical care unit (CCU) patients with suspected pneumonia at Mayo Clinic Health System Eau Claire.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
134
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Procalcitonin-guided therapyUse of procalcitonin as biomarker to guide therapyProcalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
Primary Outcome Measures
NameTimeMethod
Length of antibiotic therapyIndefinite

Participants will be followed for the entire time they are on antibiotics to treat pneumonia, an expected average of 30 total antibiotic days.

Secondary Outcome Measures
NameTimeMethod
Length of stay in critical care unitIndefinite

Participants will be followed for their entire length of stay in the critical care unit, an expected average of 7 days.

CostOnce

The average cost of antibiotics per patient, measured in US dollars, based on total antibiotic days.

Length of stay in the hospitalIndefinite

Participants will be followed their entire length of stay in the hospital, an expected average of 14 days.

Trial Locations

Locations (1)

Mayo Clinic Health System Eau Claire

🇺🇸

Eau Claire, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath